← Back to Clinical Trials
Recruiting NCT03954431

NCT03954431 High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03954431
Status Recruiting
Phase
Sponsor University of Arizona
Condition Breast Cancer
Study Type INTERVENTIONAL
Enrollment 600 participants
Start Date 2025-08-14
Primary Completion 2028-12

Eligibility & Interventions

Sex Female only
Min Age 40 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Dedicated breast CT(BCT)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 600 participants in total. It began in 2025-08-14 with a primary completion date of 2028-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is being performed to find out if a new kind of breast imaging (called dedicated breast CT or BCT) can help doctors to see the small structures in breast tissue more clearly. The investigators also want to find out if using the BCT will provide a more accurate diagnosis of breast cancer.

Eligibility Criteria

Inclusion criteria: All subjects that are eligible to participate in the study will be women who satisfy all of the inclusion criteria stated below: * who are 40 years of age or older (typical screening age range) * who are undergoing or scheduled for screening or diagnostic imaging, or need a biopsy to investigate an abnormality in the breast. Exclusion criteria: Subjects that present with any of the criteria listed below will be excluded: * Males, * women less than 40 years old, * women unable to self-consent, * prisoners, * pregnant, suspected to be pregnant, or lactating women (self-reported) * women with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker; * women who are unable to tolerate study constraints, frail, or unable to cooperate; * women who weigh more than 440 lbs (200 Kg), which is the weight limit for the patient support table of the BCT system; * women who have received radiation treatments to the thorax for malignant and nonmalignant conditions, such as (but not limited to) treatment for enlarged thymus gland as an infant, irradiation for benign breast conditions, including breast inflammation after giving birth, and treatment for Hodgkin's disease; * women who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram; * women who have received large number of diagnostic x-ray examinations for monitoring of disease such as (but not limited to) tuberculosis, and severe scoliosis.

Contact & Investigator

Central Contact

Michele Galvan, R.T.R.

✉ mngalvan@arizona.edu

📞 520-626-2279

Principal Investigator

Srinivasan Vedantham, PhD

PRINCIPAL INVESTIGATOR

University of Arizona

Frequently Asked Questions

Who can join the NCT03954431 clinical trial?

This trial is open to female participants only, aged 40 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03954431 currently recruiting?

Yes, NCT03954431 is actively recruiting participants. Contact the research team at mngalvan@arizona.edu for enrollment information.

Where is the NCT03954431 trial being conducted?

This trial is being conducted at Tucson, United States.

Who is sponsoring the NCT03954431 clinical trial?

NCT03954431 is sponsored by University of Arizona. The principal investigator is Srinivasan Vedantham, PhD at University of Arizona. The trial plans to enroll 600 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology